bioRxivPharmacology & ToxicologyPreprint
Patolakaturohiniyadi Kashayam, exerts anti-steatotic and anti-obesogenic effects via coordinated regulation of lipid metabolism, inflammation, and incretin signalling.
Sania KouseriD, Subrahmanya Kumar KukkupuniiD, Poornima Devkumar, Chethala N. VishnuprasadiD
Abstract
BackgroundMetabolic dysfunction is characterized by dysregulated lipid metabolism, lipotoxicity, insulin resistance, and chronic low-grade inflammation, contributing to obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Multi-target therapeutic strategies that restore lipid homeostasis are of growing interest. Patolakaturohiniyadi Kashayam (PKR), a classical Ayurvedic polyherbal formulation, was investigated for its potential to modulate lipid metabolism and ameliorate metabolic dysfunction. MethodsAn integrated approach combining network pharmacology, in vitro, lipidomics, and in vivo studies was employed. Hub gene identification and KEGG pathway enrichment were performed to elucidate molecular targets. Anti-steatotic and anti-adipogenic effects were assessed in hepatocytes and adipocytes, followed by lipidomic profiling. Efficacy was further evaluated in a high-fat high-fructose diet (HFHFD)-induced animal model. ResultsNetwork pharmacology identified key targets including TP53, AKT1, IL6, TNF, and STAT3, enriched in pathways related to lipid metabolism, inflammation, and metabolic regulation. PKR significantly reduced lipid droplet accumulation and intracellular triglyceride levels in vitro. Lipidomics revealed suppression of diacylglycerol-mediated lipotoxicity and restoration of phospholipid balance, characterized by increased lysophospholipids and phosphatidylethanolamines with normalization of phosphatidylcholine species. In vivo, PKR reduced body, liver, and adipose tissue weights, improved serum lipid profiles, and decreased AST and ALT levels. Histological analyses demonstrated reduced lipid accumulation and inflammation, along with preservation of adipose tissue architecture. PKR also improved glucose tolerance and significantly elevated plasma GLP-1 levels. ConclusionPKR exerts potent anti-steatotic and anti-obesogenic effects through coordinated regulation of lipid metabolism, inflammation, and incretin signalling, highlighting its potential as a multi-target therapeutics for metabolic dysfunction.
- organism: mouse
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lodhrasavam modulates liver--adipose--pancreas axis to ameliorate MASLD: Observations from In vitro and in vivo models of hepatic and metabolic dysfunction
S. Kouser, S. Kumar, V. Chethala N·bioRxiv·Jul 5, 2023
- Pharmacological inhibition of G protein-coupled receptor kinase 5 decreases high-fat diet-induced hepatic steatosis in mice
Mary E. Seramur, SANDY T. SINK, … Chia‐Chi Chuang·Biochemical and Biophysical Research CommunicationsPeer-reviewed·Dec 3, 2025
- AMPK-activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching
Emanuel Holm, Isabeau Vermeulen, … Andreas Hörnblad·JCI InsightPeer-reviewed·Apr 7, 2025
- Pyrroloquinoline Quinone inhibits PCSK9, augments LDLR recycling and enhances the effect of atorvastatin
K. V. Devasani, A. Majumdar, … R. Kaul·bioRxiv·Mar 20, 2022
- Protein tyrosine phosphatase receptor kappa regulates glycolysis and de novo lipogenesis to promote hepatocyte metabolic reprogramming in obesity
E. H. Gilglioni, A. Li, … E. N. Gurzov·bioRxiv·Dec 1, 2023
- Deletion or inhibition of PTPRO mitigates diet-induced hepatic steatosis and inflammation in obesity
T. Shintani, R. Suzuki, … M. Noda·bioRxiv·Sep 5, 2022